Compare HRMY & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | GILT |
|---|---|---|
| Founded | 2017 | 1987 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2020 | 1997 |
| Metric | HRMY | GILT |
|---|---|---|
| Price | $31.05 | $18.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $44.11 | $19.00 |
| AVG Volume (30 Days) | ★ 793.3K | 559.1K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $868,453,000.00 | N/A |
| Revenue This Year | $19.75 | $15.06 |
| Revenue Next Year | $12.88 | $11.72 |
| P/E Ratio | ★ $12.04 | $42.82 |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $5.43 |
| 52 Week High | $40.87 | $20.56 |
| Indicator | HRMY | GILT |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 54.66 |
| Support Level | $25.92 | $15.96 |
| Resistance Level | $30.96 | $19.85 |
| Average True Range (ATR) | 1.47 | 0.85 |
| MACD | 0.07 | 0.12 |
| Stochastic Oscillator | 35.36 | 58.97 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.